argenx SE (ARGNF)
USD 697.42
(0.33%)
USD 697.42
(0.33%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.22 Billion USD | 198.56% |
| 2022 | 410.74 Million USD | -17.4% |
| 2021 | 497.27 Million USD | 1009.97% |
| 2020 | 44.8 Million EUR | -42.69% |
| 2019 | 78.16 Million EUR | 218.1% |
| 2018 | 24.57 Million EUR | -43.75% |
| 2017 | 43.68 Million EUR | 182.33% |
| 2016 | 15.47 Million EUR | 106.49% |
| 2015 | 7.49 Million EUR | 64.07% |
| 2014 | 4.56 Million EUR | 23.56% |
| 2013 | 3.69 Million EUR | 69.3% |
| 2012 | 2.18 Million EUR | 49.75% |
| 2011 | 1.45 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 877.26 Million USD | 118.77% |
| 2024 Q1 | 401 Million USD | -1.58% |
| 2023 Q1 | 219.14 Million USD | 25.83% |
| 2023 Q2 | 270.55 Million USD | 23.46% |
| 2023 FY | 1.22 Billion USD | 198.56% |
| 2023 Q4 | 407.43 Million USD | 23.54% |
| 2023 Q3 | 329.78 Million USD | 21.9% |
| 2022 Q4 | 174.16 Million USD | 26.22% |
| 2022 Q2 | 75.19 Million USD | 221.18% |
| 2022 Q1 | 23.41 Million USD | -10.03% |
| 2022 Q3 | 137.98 Million USD | 83.5% |
| 2022 FY | 410.74 Million USD | -17.4% |
| 2021 FY | 497.27 Million USD | 1009.97% |
| 2021 Q1 | 158.15 Million EUR | 4354.65% |
| 2021 Q2 | 312.24 Million USD | 97.43% |
| 2021 Q3 | 857 Thousand USD | -99.73% |
| 2021 Q4 | 26.02 Million USD | 2936.41% |
| 2020 Q4 | -3.71 Million USD | -132.41% |
| 2020 Q3 | 11.46 Million EUR | 0.0% |
| 2020 FY | 44.8 Million EUR | -42.69% |
| 2019 FY | 78.16 Million EUR | 218.1% |
| 2019 Q1 | 40.93 Million EUR | 2779.29% |
| 2019 Q2 | 8.55 Million EUR | -79.09% |
| 2019 Q3 | 8.73 Million EUR | 2.02% |
| 2019 Q4 | 17.51 Million EUR | 100.63% |
| 2018 Q4 | 1.42 Million EUR | -41.83% |
| 2018 Q2 | 13.84 Million EUR | 101.54% |
| 2018 Q1 | 6.86 Million EUR | -33.43% |
| 2018 FY | 24.57 Million EUR | -43.75% |
| 2018 Q3 | 2.44 Million EUR | -82.34% |
| 2017 Q1 | 7.11 Million EUR | 93.52% |
| 2017 FY | 43.68 Million EUR | 182.33% |
| 2017 Q4 | 10.31 Million EUR | 34.09% |
| 2017 Q3 | 7.69 Million EUR | -58.56% |
| 2017 Q2 | 18.56 Million EUR | 160.87% |
| 2016 Q4 | 3.67 Million EUR | -33.21% |
| 2016 FY | 15.47 Million EUR | 106.49% |
| 2016 Q3 | 5.5 Million EUR | 45.64% |
| 2016 Q2 | 3.77 Million EUR | 50.51% |
| 2016 Q1 | 2.51 Million EUR | 32.96% |
| 2015 FY | 7.49 Million EUR | 64.07% |
| 2015 Q4 | 1.88 Million EUR | -26.43% |
| 2015 Q3 | 2.56 Million EUR | 48.66% |
| 2015 Q2 | 1.72 Million EUR | 31.8% |
| 2015 Q1 | 1.31 Million EUR | -26.42% |
| 2014 FY | 4.56 Million EUR | 23.56% |
| 2014 Q4 | 1.78 Million EUR | -11.35% |
| 2014 Q2 | 308.66 Thousand EUR | -34.19% |
| 2014 Q1 | 468.98 Thousand EUR | -49.81% |
| 2014 Q3 | 2 Million EUR | 550.83% |
| 2013 Q3 | 1.67 Million EUR | 215.1% |
| 2013 Q2 | 530.61 Thousand EUR | -5.18% |
| 2013 Q4 | 934.37 Thousand EUR | -44.12% |
| 2013 FY | 3.69 Million EUR | 69.3% |
| 2013 Q1 | 559.62 Thousand EUR | 0.0% |
| 2012 FY | 2.18 Million EUR | 49.75% |
| 2011 FY | 1.45 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -1619354.862% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -6631.343% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -897.379% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -63373.913% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -7674.78% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -6959300.715% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -5609.638% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -1865643.671% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -20677.974% |
| Marizyme, Inc. | 645.81 Thousand USD | -189788.048% |
| Genus plc | 668.8 Million USD | -83.361% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | -399.892% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -1238678.108% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -298881.142% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -1597476.895% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -3103083.359% |
| MultiCell Technologies, Inc. | 49.32 USD | -2486447588.564% |
| ONE Bio Corp. | 52.29 Million USD | -2244.943% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -2366.394% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -2507703.681% |
| Q BioMed Inc. | 284.35 Thousand USD | -431166.88% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -4043.379% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | -745.154% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -219784.169% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -1751780.0% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -186128.702% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 91.652% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -122754254.354% |
| Enzolytics Inc. | 52.79 Thousand USD | -2322644.147% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -201422.698% |
| MetaStat, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -874328.488% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -198530.998% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | -46.072% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -122811.1% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -2436.121% |
| BioStem Technologies, Inc. | 16.68 Million USD | -7249.633% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -518295.333% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -518295.333% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -89477.502% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -258763.91% |
| SYBLEU INC | 11.69 Thousand USD | -10484817.921% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -15644.203% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -9433100.0% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -3101827.455% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -36726.306% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -18299.34% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -117928.489% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -4659.25% |
| CSL Limited | 14.8 Billion USD | 91.714% |
| Cellectis S.A. | 755 Thousand USD | -162325.96% |